Communiqués Sernova Biotherapeutics Inc

Actions

SVA

CA81752F1062

Equipement, fournitures et distribution médicale

Cours en clôture Toronto S.E. Autres places de cotation 02/07/2026			Varia. 5j.	Varia. 1 janv.
0,1300 ^CAD	-3,70%		-7,14%	-

17/06	Sernova : désignation de médicament orphelin pour sa transplantation d'îlots autologues dans la prévention du diabète de type 3c	MT
11/06	Sernova Biotherapeutics Inc publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 avril 2026	CI

Communiqués

17/06	Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy	AQ
23/04	Sernova Biotherapeutics Announces Closing of Recently Approved Financings	NE
09/04	Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders	NE
24/03	Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing	NE
16/03	Sernova Biotherapeutics : 2026 Q1 MD&A	PU
16/03	Sernova Biotherapeutics : 2026 Q1 Financial Statements	PU
09/03	Sernova Biotherapeutics : Appointment of Proxyholder (SVA 2026 Proxy)	PU
09/03	Sernova Biotherapeutics : Voting Instruction Form (VIF) (SVA 2026 VIF)	PU
09/03	Sernova Biotherapeutics : Combined Circular with Schedules (SVA 2026 Combined Circular w Schedules)	PU
04/03	Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval	NE
20/02	Sernova Biotherapeutics Announces Warrant Amendments	NE
12/01	Sernova Biotherapeutics : 2025 Annual Information Form	PU
12/01	Sernova Biotherapeutics : 2025 Q4 MD&A	PU
12/01	Sernova Biotherapeutics : 2025 Q4 Financial Statements	PU
13/11	Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts	NE
01/10/25	Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang	NE
23/09/25	Sernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors	AQ
08/09/25	Sernova Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investor Conference	AQ
16/06/25	Sernova Biotherapeutics : 2025 Q2 MD&A	PU
16/06/25	Sernova Biotherapeutics : 2025 Q2 Financial Statements	PU
02/06/25	Sernova Appoints Jonathan Rigby as Interim Chair	AQ
26/05/25	Chair of Sernova Biotherapeutics Resigns	AQ
22/05/25	Sernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes	AQ
14/05/25	Sernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 Diabetes	AQ
17/04/25	Sernova Biotherapeutics Secures $4 Million Loan to Further Advance its Clinical Development Plans	AQ